阿坦色林 | 76330-71-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 阿坦色林
• 中文别名: 3-[2-[4-(4-氟苯甲酰基)-1-哌啶]乙基]-2,3-二氢-2-硫氧代-4(1H)-喹唑烷酮盐酸盐；3-[2-[4-(4-氟苯甲酰基)哌啶-1-基]乙基]-2-硫酮-1H-喹唑啉-4-酮；阿坦塞林
• 英文名称: Altanserin
• 英文别名: 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
• CAS: 76330-71-7
• 化学式: C₂₂H₂₂FN₃O₂S
• 分子量: 411.5
• InChiKey: SMYALUSCZJXWHG-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜：>5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  54
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36
• 安全说明：
  S26
• 危险性防范说明：
  P264,P280,P305+P351+P338,P337+P313
• 危险性描述：
  H319

反应信息

• 作为反应物：
  描述：

  阿坦色林 在 potassium [¹⁸F]fluoride 、 potassium carbonate 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 生成 [18F]altanserin
  参考文献：
  名称：

  Baldwin, R. M.; Tan, P.-Z.; Dyck, C. H. Van, Journal of Labelled Compounds and Radiopharmaceuticals, 1997, vol. 40, p. 133 - 135

  摘要：

  DOI：

文献信息

• [EN] DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO<br/>[FR] DERIVES DE DIARYL ET ARYLHETEROARYL UREE UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA SEROTONINE 5-HT2A UTILES POUR LA PROPHYLAXIE ET LE TRAITEMENT DE TROUBLES ASSOCIES A CE DERNIER
  申请人：ARENA PHARM INC

  公开号：WO2005012254A1

  公开（公告）日：2005-02-10

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明涉及某些Formula (I)的吡唑衍生物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。该类化合物及其药物组合物用于预防或治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、心房颤动、减少血凝块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、吉尔·德·拉·图雷特综合征、躁狂症、器质性或NOS精神病、精神病性障碍、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、睡眠障碍、糖尿病相关疾病等的方法。本发明还涉及预防或治疗5-HT2A 5-羟色胺受体介导的疾病的方法，结合多巴胺D2受体拮抗剂如氟哌啶醇，分别或联合给药。
• [EN] COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：EXCIVA UG HAFTUNGSBESCHRAENKT

  公开号：WO2018039642A1

  公开（公告）日：2018-03-01

  Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

  提供具有公式I的化合物(I)或其对应异构体、代谢物、衍生物、氘化衍生物、卤化衍生物、前药、药用可接受盐、N-氧化物或其组合，以及它们的制备过程和中间体、组合物和使用方法。包含公式I化合物的药物组合物以及公式II的化合物(IIa) (IIb)或其对应异构体、代谢物、衍生物、氘化衍生物、前药、药用可接受盐、N-氧化物或其组合。包含共给予需要该物质的受试者公式I化合物或SARPO和公式II化合物或DEX的DEX效能改进或提供DEX有益药代动力学效果的组合物和方法，以及剂量形式、药物传递系统、治疗方法。
• [EN] NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF<br/>[FR] PETITES CELLULES MODULANT LE PDI NEUROPROTECTEUR ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2020113222A1

  公开（公告）日：2020-06-04

  The present disclosure provides, inter alia, compounds and compositions having the formula (I) as defined herein. Methods of using and making such compounds and compositions are also provided. The present disclosure further provides screening methods, including detectable probes as well as diagnostic methods and methods for monitoring the progress of a disease, such as a neurodegenerative disease.

  本公开提供具有以下式(I)所定义的化合物和组合物，等等。还提供使用和制备这种化合物和组合物的方法。本公开还提供筛选方法，包括可检测的探针，以及诊断方法和监测疾病进展的方法，如神经退行性疾病。
• [EN] SUBSTITUTED 3-HETEROARYLOXY-3-(HETERO)ARYL-PROPYLAMINES AS SEROTONIN TRANSPORTER AND SEROTONIN HT2C RECEPTOR MODULATORS<br/>[FR] 3-HÉTÉROARYLOXY-3-(HÉTÉRO)ARYL-PROPYLAMINES SUBSTITUÉES COMME MODULATEURS DE TRANSPORTEUR DE LA SÉROTONINE ET DU RÉCEPTEUR HT2C DE LA SÉROTONINE
  申请人：AAPA B V

  公开号：WO2014046544A1

  公开（公告）日：2014-03-27

  The present invention relates to compounds compound according to Formula (1): and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have serotonin (5-HT) transporter inhibitory effects and 5-HT 2C receptor antagonist or inverse agonist effects. The present invention also relates to pharmaceutical compositions comprising these compounds, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

  本发明涉及按照式（1）的化合物和其药学上可接受的盐、水合物和溶剂合物。这些化合物具有血清素（5-HT）转运体抑制作用和5-HT 2C 受体拮抗剂或逆激动剂作用。本发明还涉及包含这些化合物的药物组合物，以及将它们用于预防或治疗中枢神经系统疾病的方法。
• [EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR TRAITER DES TROUBLES ASSOCIÉS AUX RÉCEPTEURS 5-HT1A ET 5-HT2A
  申请人：ACHE LAB FARMACEUTICOS SA

  公开号：WO2012037634A1

  公开（公告）日：2012-03-29

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  这项发明涉及与烷基-哌嗪基苯基4(3H)-喹唑啉酮通式(I)化合物相关，这些化合物在药理学上活跃，并能通过促进对5-HT1A和5-HT2A 5-羟色胺受体的作用来控制、缓解或治疗与这些受体相关的疾病，并且含有这些化合物的药物组合物用于治疗与这些受体相关的疾病。这些化合物及其药物组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、恐慌、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等疾病方面具有用处，这些疾病与这些受体有关。